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A B S T R A C T
Diabetes is a major public health problem in the world and one of the leading causes of morbidity and mortality from
cardiovascular and chronic kidney disease. Aging of the population is expected to further increase the prevalence of type
2 diabetes, particularly in the age group over 65. According to the 2011 census, in Croatia, 17.7% of the population were
elderly, and the estimated prevalence of diabetes in this age group is 15–20%. Taking care of elderly diabetics has its own
characteristics compared to other age groups, and a particular challenge for the family physician due to comorbidity and
polymedication, as well as more frequent complications of the disease and more common side effects of treatment. The
aim of this article is to show the treatment of diabetes in elderly, in the light of new studies (ACCORD, ADVANCE and
VADT), and to present revised professional societies (ADA, AHA, ACC) recommendations, focusing on the individualized
approach.
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Introduction
According to the World Health Organization (WHO),
more than 347 million people worldwide have diabetes1,
and it is estimated that 40% of people with the disease
are elderly, aged ³65 years2. According to data from the
International Diabetes Federation (IDF) prevalence of
diabetes in the age group 20–79 years was in 2007, 6%,
while the prevalence in the elderly is estimated at 15–
20%3. Aging significantly increases the incidence of dia-
betes, and the highest is recorded in the subgroup of
60–74 years (17.6%)4. 80–95% of diabetics suffer from
type 2 diabetes caused by increased peripheral insulin re-
sistance and the consequent failure of b-cell function.
The burden of macrovascular and microvascular compli-
cations of diabetes is enormous. Diabetics live 5–10 years
less than their healthy peers, with 8 times higher cardio-
vascular risk, and the cause of death in more than 50% of
cases is from cardiovascular disease. Diabetes is a signifi-
cant cause of disability: the risk of amputations is 20
times higher in diabetics compared to non-diabetic gen-
eral population of the same age. Diabetic retinopathy is
the most common cause of blindness in developed coun-
tries, and diabetic nephropathy is the reason for perma-
nent renal replacement therapy5,6. Rates of all the afore-
mentioned complications are the most common in elderly
diabetics.
Thus, diabetes is an important public health priority
everywhere in the world, and one of the most important
causes of morbidity and mortality, burdening individuals,
communities and health systems of many countries, in-
cluding Croatia. Croatian population ages, which is an
advantageous cultural, civilizational and anthropological
trend. Thus, according to 2011 census, 17.7% persons
aged ³65 years7, lived in Croatia, significantly more than
in the previous census in 2001, when the figure was
15.6%. Population is aging rapidly, therefore, family doc-
tors (FDs) can expect more and more elderly people with
type 2 diabetes in their offices, in a continuous process of
long-term care, monitoring and treatment. As the group
of elderly is extremely heterogeneous, diabetes in the el-
derly is particularly challenging for FD.
The aim of this article is to present the specificity of
diabetes in the elderly, therapeutic targets for this grow-
ing population group, as well as to present new profes-
sional societies recommendations based on the results of
recent studies.
Materials and Methods
Authors of the article searched bibliographic database
Medline/Pubmed using keywords: type 2 diabetes, el-
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derly. Limits of the search were set to: clinical studies,
randomized clinical trials. Diabetic and geriatric guide-
lines published in the last 5 years were also included.
Results
We found 176 studies and firstly check them by the ti-
tles and abstracts to see if they were fulfilling the crite-
ria. Only 20 that fulfilled inclusion criteria were in-
cluded, fully reviewed and summarized in this review
article.
The elderly population is very heterogeneous, con-
taining within itself a very large interindividual varia-
tions. Physiological process of aging depends on both ge-
netic and environmental factors, as well as the presence
of disease can significantly accelerate the aging process.
One should distinguish the concept of chronological (cal-
endar) and physiological (cellular) age. Biological age es-
timate is based on assessment of cardiovascular, respira-
tory system as well as renal function8. The population of
elderly people are on one side of the »spectrum« »old
youngsters« with preserved physiological function and
functional capacity above expected levels for age and, on
the other hand the same »spectrum« hard empowered se-
niors (frailty syndrome), which are weak, exhausted and
dependent on the help of others9. The concept of popula-
tion heterogeneity in older people with diabetes is the
foundation of an individualized care for elderly diabetics.
This individualized approach involves synergism of
nonpharmacologic and pharmacologic measures. Non-
-pharmacological counseling aims for lifestyle changes
(diet, exercise, self-control), and pharmacological means
prescribing medications. When choosing medications for
elderly diabetics, one should take into account side ef-
fects of some (hypoglycemia, weight gain, fluid retention,
gastrointestinal disorders, flatulence), contraindications
or appropriate dose adjustment for individual patients
(hypoxia, congestive heart failure, renal impairment)10
but also adjust prescription to the patient’s personal
choice, prognosis and comorbidity, always taking into ac-
count the quality of life. In »biologically younger« elderly,
with longer life expectancy goals of glycemic control are
equal as in adults aged <65 years, and the same recom-
mendations for nonsmoking, regular exercise, maintain-
ing a normal BMI, target blood pressure and hyperlipi-
demia apply11. But in those »biologically older« target
HbA1c is shifted towards higher proportionally with in-
creasing age, reduced functional abilities, cognitive ca-
pacities and ability for self-care.
The therapeutic goals of glycemic control, blood pres-
sure, and hyperlipidemia in elderly diabetics according to
Kirkman MS and colleagues12 are shown in Table 1.
Discussion
It seems that the goals of glycemic control in elderly
patients are similar to those of younger age groups, but
recently appeared some doubt on the need for vigorous
glycemic control. Those doubts appeared in light of the
results of recent studies ACCORD (Action to Control
Cardiovascular Risk in Diabetes), ADVANCE (Action in
Diabetes and vascular Disease) and VADT (Veterans Af-
fairs Diabetes Trial)13–15.
Specifically, the studies ACCORD was discontinued
earlier because it demonstrated increased mortality in
the intervention group subjects (with strict glycemic con-
trol, with the goal of HbA1c <6%) compared to the con-
trol group (with standard care with the goal of HbA1c
7.0–7.9%), and that in subsequent analyzes could not be
attributed only to hypoglycemic incidents. However, the
number of myocardial infarction, stroke, and total CV
mortality in a post hoc analysis was indeed lower in the
intervention group, but not statistically significant, which
was the reason for mentioned dilemma13.
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TABLE 1
A FRAMEWORK FOR CONSIDERING TREATMENT GOALS FOR GLYCEMIA, BLOOD PRESSURE
AND DYSLIPIDEMIA IN OLDER ADULTS WITH DIABETES













<7.5% 5.0–7.2 5.0–8.3 <140/80 Statin (if no contraindica-tions or side effects)
Complex with multiple
comorbidity, poor func-
tional ability, mild to
moderate cognitive
impairment)




The risk of falls and frac-
tures
<8.0% 5.0–8.3 5.6–10.0 <140/80 Statin (if no contraindica-tions or side effects)
Weak functionally inca-




The benefit of the treat-
ment questionable
<8.5% 5.6–10.0 6.2–11.1 <150/90
Statin? Assess the poten-
tial benefit (more in sec-
ondary than primary
***CVD prevention)
*Target value of HbA1c, **Fasting glycemia (mmol/L), ***CVD – cardiovascular disease
In ADVANCE study conducted in Europe, Canada,
Asia, New Zealand and Australia in more than 1,000 pa-
tients, intensified glycemic control resulted in a signifi-
cant reduction in microvascular complications, while the
impact on those macrovascular did not14. VADT study
showed that in the group with intensified glucoregu-
lation the number of cardiovascular events (myocardial
infarction, stroke) or amputations was not lower com-
pared to standard care group. Mortality in intensively
treated was even slightly higher, but not statistically
significant15.
Two large controlled studies, which are considered
the cornerstone of modern diabetology, the Diabetes
Control and Complications Trial (DCCT) and the UK
Prospective Diabetes Study (UKPDS)16,17 showed signifi-
cant and continuous reduction of microvascular compli-
cations in intensively treated type 1 diabetics (DCCT) as
well as type 2 (UKPDS) compared to the control group of
standard care. In DCCT reduction of microvascular com-
plications in intensified treatment group was 60%, (25%
in the UKPDS), while in macrovascular the figures were
42% and 18%16,17. Results of DCCT and UKPDS studies
have prompted the American Diabetes Association (ADA)
in 2008 to recommend target HbA1c <7% for most
adults with diabetes as the standard of care18. But stud-
ies ACCORD, ADVANCE and VADT, prompted three
American expert of the American Diabetes Association
(ADA), the American Heart Association (AHA) and Ame-
rican College of Cardiology (ACC) to revisit and revise
their earlier recommendations for goals of glucoregu-
lation. ADA has announced these changes in its execu-
tive summary in 201319.
How can significant differences in the results of the
DCCT and UKPDS studies and three newer ADVANCE,
ACCORD and VADT be explained? ADVANCE, ACCORD
and VADT studies were carried out on a sample of pa-
tients with already established diagnosis of diabetes and
a relatively long history of the existence of the disease of
8–10 years, while respondents from the DCCT and UKPDS
were newly diagnosed, without atherosclerotic complica-
tions, thus »caught« at an earlier stage development of
their disease. From this we can conclude that early inten-
sified glycemic control (as being undertaken in the DCCT
and UKPDS) gives much better results and greater bene-
fits for patients in terms of reducing microvascular and
macrovascular complications of diabetes than »delayed«
intensified interventions undertaken in patients with ad-
vanced disease (ACCORD, ADVANCE) or older (VADT).
So, one should think carefully when treating with ad-
vanced diabetes, which is almost the case in elderly, and
take into account possible adverse effects (hypoglycemia,
weight gain, metabolic changes)20. In such patients indi-
vidualized goals of glycemic control should be set, as fol-
lows:
In patients with a short history of diabetes, without
significant CV disease, and with life expectancy more
then 10 years, targeted HbA1c can be less then 7%, but
taking into account the risk of hypoglycaemia. The risk
of hypoglycemia is increased in the elderly, can cause pos-
tural instability, falls and fractures, and cause perma-
nent cognitive impairment. Elderly are more vulnerable
to hypoglycemia, and its occurrence is a warning sign
that a doctor should take »step down« in glycemic control
In patients prone to hypoglycemia, with a long his-
tory of diabetes, advanced microvascular or macrovas-
cular complications, life expectancy <10 years, as well as
severe comorbid diseases, target HbA1c should be slightly
higher, HbA1c <8%.
These recommendations were adopted by American
Geriatric Society and the European Diabetes Working
Party in its guidelines, stressing the importance of indi-
vidualized goals in glycemic control of the elderly12,21,22.
Conclusion
In everyday care for an older person with diabetes,
FDs must approach them individually, taking into ac-
count reliable evidence in the field of diabetology and rele-
vant professional societies guidelines. It is crucial to assess
patient’s biological age, functional capacity, comorbidi-
ties, polymedication but also his/her needs, biopsychoso-
cial context, personal choices and quality of life.
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DIJABETES KOD STARIJIH OSOBA
S A @ E T A K
Dijabetes je veliki javnozdravstveni problem u svijetu i jedan od vode}ih uzroka morbiditeta i mortaliteta kod kar-
diovaskularnih bolesti i kroni~ne bubre`ne bolesti. Starenjem populacije o~ekuje se daljnji porast prevalncije dijabtesa
tipa 2, posebno kod starijih od 65 godina. Prema popisu stanovni{tva iz 2011. godine, 17,7% stanovni{ta je bilo starije od
65 godina a procijenjuje se da je prevalencija dijabetesa u toj dobnoj skupini 15–20%. Zbrinjavanje starijih dijabeti~ara u
odnosu na druge dobne skupine je specifi~no i predstavlja poseban izazov za obiteljske lije~nike zbog ~estog komor-
biditeta i polimedikacije, ~e{}ih komplikacija bolesti i u~estalih nuspojava lije~enja. Cilj ovog ~lanka je prikazati lije~enje
starijih dijabeti~ara, u svijetlu novih studija (ACCORD, ADVANCE and VADT) te prikazati preporuke profesionalnih
dru{tava (ADA, AHA, ACC) fokusiraju}i se na individualan pristup pacijentu.
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